NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Announces JCO Publication on MammaPrint Utility in NRG/NSABP B-42 Trial
MammaPrint 70-gene Assay Evaluated in the NRG Oncology/NSABP B-42 Trial
Read MoreMammaPrint High 2 tumors exhibit heightened immune active state
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer
Read MoreMammaPrint & 3-year outcome of CT with/without anthracycline-ASCO 2024
Association of MammaPrint index and 3-year outcome of patients in the FLEX Registry trial with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline
Read MoreAgendia to Unveil Robust Suite of Data at 2024 ASCO
Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
Read MoreGerman Gynecological Oncology Group (AGO) includes BluePrintยฎ in Guidelines
German Gynecological Oncology Group (AGO) Recognizes BluePrintยฎ in Breast Cancer Guidelines
Read MoreAgendia Announces New I-SPY2 Data Showcasing Ability of New Signature ImPrintTN
Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer
Read MoreAgendia Presents Data from FLEX Study at Miami Breast 2024
Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrintยฎ + BluePrintยฎโs Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
Read More